Skip to Content

30 Results Found

  • Article
  • Open Access
28 Citations
4,195 Views
11 Pages

Influence of Disease Duration on Circulating Levels of miRNAs in Children and Adolescents with New Onset Type 1 Diabetes

  • Nasim Samandari,
  • Aashiq H. Mirza,
  • Simranjeet Kaur,
  • Philip Hougaard,
  • Lotte B. Nielsen,
  • Siri Fredheim,
  • Henrik B. Mortensen and
  • Flemming Pociot

21 November 2018

Circulating microRNAs (miRNAs) have been implicated in several pathologies including type 1 diabetes. In the present study, we aimed to identify circulating miRNAs affected by disease duration in children with recent onset type 1 diabetes. Forty chil...

  • Article
  • Open Access
9 Citations
2,889 Views
9 Pages

Prospective Study of 4 Gy Radiotherapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma (FORMAL)

  • Jaehyeon Park,
  • Ji Woon Yea,
  • Se An Oh,
  • Min Kyoung Kim,
  • Jun Hyuk Son and
  • Jae Won Park

1 September 2022

External beam radiotherapy is effective for stage I orbital mucosa-associated lymphoid tissue lymphoma (MALToma). Hence, very-low-dose radiotherapy is increasingly being investigated. We conducted a single-center prospective phase II trial to evaluat...

  • Article
  • Open Access
30 Citations
5,395 Views
12 Pages

Influence of Age on Partial Clinical Remission among Children with Newly Diagnosed Type 1 Diabetes

  • Stefano Passanisi,
  • Giuseppina Salzano,
  • Albino Gasbarro,
  • Valentina Urzì Brancati,
  • Matilde Mondio,
  • Giovanni Battista Pajno,
  • Angela Alibrandi and
  • Fortunato Lombardo

Partial clinical remission (PCR) is a transitory period characterized by the residual endogenous insulin secretion following type 1 diabetes (T1D) diagnosis and introducing the insulin therapy. Scientific interest in PCR has been recently increasing,...

  • Article
  • Open Access
1,447 Views
13 Pages

Maintenance Treatment with 5-Azacitidine in Patients with Acute Myeloblastic Leukemia Ineligible for Intensive Treatment and with Response After Induction Chemotherapy: A Phase II Clinical Trial

  • Alfonso Fernández Fernández,
  • María García Fortes,
  • Mar Tormo Díaz,
  • María Luz Juan Marco,
  • Rebeca Cuello García,
  • Adolfo de La Fuente,
  • Josefina Serrano López,
  • Mª Ángeles Medina Pérez,
  • Miguel Ángel Sánchez Chaparro and
  • Regina García Delgado

18 August 2025

Background/Objectives: After first-line treatment, elderly patients with acute myeloid leukemia (AML) often become unfit to continue intensive chemotherapy despite having achieved a response. This trial aimed to determine the efficacy of maintenance...

  • Article
  • Open Access
8 Citations
6,660 Views
12 Pages

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

  • Fatih M. Uckun,
  • Justin Watts,
  • Alice S. Mims,
  • Prapti Patel,
  • Eunice Wang,
  • Paul J. Shami,
  • Elizabeth Cull,
  • Cynthia Lee,
  • Christopher R. Cogle and
  • Tara L. Lin

21 October 2021

We evaluate the risk, characteristics and biomarkers of treatment-emergent cytokine release syndrome (CRS) in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received APVO436 during the dose-escala...

  • Article
  • Open Access
11 Citations
7,418 Views
13 Pages

Supplementation of Reduced Gluten Barley Diet with Oral Prolyl Endopeptidase Effectively Abrogates Enteropathy-Associated Changes in Gluten-Sensitive Macaques

  • Karol Sestak,
  • Hazel Thwin,
  • Jason Dufour,
  • David X. Liu,
  • Xavier Alvarez,
  • David Laine,
  • Adam Clarke,
  • Anthony Doyle,
  • Pyone P. Aye and
  • Charles P. Moehs
  • + 1 author

28 June 2016

Celiac disease (CD) is an autoimmune disorder that affects approximately three million people in the United States. Furthermore, non-celiac gluten sensitivity (NCGS) affects an estimated additional 6% of the population, e.g., 20 million in the U.S. T...

  • Article
  • Open Access
4 Citations
2,797 Views
17 Pages

Ion Mobility Spectrometry for the Metabolomic Study of Inflammatory Bowel Disease Using the Volatile Organic Compounds Profile in Human Serum and Urine

  • María García-Nicolás,
  • María Carmen Pérez-Álvarez,
  • Fuensanta Abellán-Alfocea,
  • Natalia Arroyo-Manzanares,
  • Natalia Campillo,
  • Blanca del Val-Oliver,
  • Enrique Jiménez-Santos,
  • José Zarauz-García,
  • Luis Sáenz and
  • Pilar Viñas

Inflammatory bowel disease (IBD) is an immune-mediated disease characterized by chronic mucosal inflammation of the digestive tract. The IBD diagnosis is currently based on the results of imaging, clinical, and histopathological tests. The gold stand...

  • Feature Paper
  • Article
  • Open Access
31 Citations
5,168 Views
19 Pages

26 December 2019

Combretastatin A1 (OXi4503) is a dual-function drug with vascular disrupting and cytotoxic properties that has exhibited single-agent anti-leukemia activity in murine xenograft models of acute myeloid leukemia (AML) and in a prior Phase 1A clinical s...

  • Article
  • Open Access
5 Citations
2,027 Views
24 Pages

Unveiling the Mechanisms of a Remission in Major Depressive Disorder (MDD)-like Syndrome: The Role of Hippocampal Palmitoyltransferase Expression and Stress Susceptibility

  • Careen A. Schroeter,
  • Anna Gorlova,
  • Michael Sicker,
  • Aleksei Umriukhin,
  • Alisa Burova,
  • Boris Shulgin,
  • Sergey Morozov,
  • Joao P. Costa-Nunes and
  • Tatyana Strekalova

5 January 2025

Post-translational modifications of proteins via palmitoylation, a thioester linkage of a 16-carbon fatty acid to a cysteine residue, reversibly increases their affinity for cholesterol-rich lipid rafts in membranes, changing their function. Little i...

  • Review
  • Open Access
4 Citations
7,247 Views
23 Pages

26 October 2024

Nutrition is an essential part of therapy for type 1 diabetes and is constantly evolving, offering growing opportunities to prevent this disease, slow down its evolution, and mitigate it. An attempt was made to bring together the current state of kno...

  • Article
  • Open Access
2,041 Views
18 Pages

Longitudinal Characterization of Immune Response in a Cohort of Children Hospitalized with Multisystem Inflammatory Syndrome

  • Laura Dotta,
  • Daniele Moratto,
  • Marco Cattalini,
  • Sara Brambilla,
  • Viviana Giustini,
  • Antonella Meini,
  • Maria Federica Girelli,
  • Manuela Cortesi,
  • Silviana Timpano and
  • Raffaele Badolato
  • + 12 authors

16 June 2023

Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of SARS-CoV-2 infection caused by hyperactivation of the immune system. Methods: this is a retrospective analysis of clinical data, biochemical parameters, and...

  • Article
  • Open Access
10 Citations
3,936 Views
16 Pages

Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG)

  • Bożena Katarzyna Budziszewska,
  • Aleksander Salomon-Perzyński,
  • Katarzyna Pruszczyk,
  • Joanna Barankiewicz,
  • Agnieszka Pluta,
  • Grzegorz Helbig,
  • Anna Janowska,
  • Marta Kuydowicz,
  • Łukasz Bołkun and
  • Ewa Lech-Marańda
  • + 19 authors

20 August 2021

Acute myeloid leukemia (AML) in older unfit patients is a therapeutic challenge for clinical hematologists. We evaluated the efficacy and safety of a novel low-intensity regimen consisting of low-dose cytarabine and cladribine (LD-AC+cladribine) in f...

  • Article
  • Open Access
36 Citations
9,087 Views
22 Pages

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Fatih M. Uckun,
  • Tara L. Lin,
  • Alice S. Mims,
  • Prapti Patel,
  • Cynthia Lee,
  • Anoush Shahidzadeh,
  • Paul J. Shami,
  • Elizabeth Cull,
  • Christopher R. Cogle and
  • Justin Watts

15 August 2021

APVO436 is a recombinant T cell-engaging humanized bispecific antibody designed to redirect host T cell cytotoxicity in an MHC-independent manner to CD123-expressing blast cells from patients with hematologic malignancies and has exhibited single-age...

  • Article
  • Open Access
423 Views
15 Pages

The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System

  • Julia Wendler,
  • Benjamin Kasenda,
  • Eliza M. Lauer,
  • Kudret Kama,
  • Lisa Kristina Isbell,
  • Dominik Marschner,
  • Florian Scherer,
  • Natalie Malenica,
  • Cora Gloggengiesser and
  • Gerald Illerhaus
  • + 2 authors

30 January 2026

Background/Objectives: Relapsed and refractory (rr) primary large B-cell lymphoma of the central nervous system (PCNSL) has a dismal prognosis, and the standard of care is not established. The most common genetic imbalance includes the B-cell lymphom...

  • Article
  • Open Access
2,037 Views
20 Pages

A Comparison of the Efficacy and Safety of Ustekinumab and Upadacitinib in Biologically Experienced Ulcerative Colitis Patients

  • Osman Özdoğan,
  • Serkan Yaraş,
  • Mehmet Kasım Aydın,
  • Fehmi Ateş,
  • Engin Altıntaş and
  • Orhan Sezgin

Background/Objectives: Ustekinumab (UST) and upadacitinib (UPA) are molecules that have been used in patients with ulcerative colitis (UC) since 2019 and 2022, respectively. Both agents are generally preferred for biologically experienced UC patients...

  • Feature Paper
  • Article
  • Open Access
7 Citations
6,090 Views
27 Pages

Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes: miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion

  • Laia Gomez-Muñoz,
  • David Perna-Barrull,
  • Marta Murillo,
  • Maria Pilar Armengol,
  • Marta Alcalde,
  • Marti Catala,
  • Silvia Rodriguez-Fernandez,
  • Sergi Sunye,
  • Aina Valls and
  • Marta Vives-Pi
  • + 2 authors

28 February 2023

The partial remission (PR) phase of type 1 diabetes (T1D) is an underexplored period characterized by endogenous insulin production and downmodulated autoimmunity. To comprehend the mechanisms behind this transitory phase and develop precision medici...

  • Article
  • Open Access
3 Citations
2,572 Views
14 Pages

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups

  • Susana Vives,
  • David Quintela,
  • Mireia Morgades,
  • Isabel Cano-Ferri,
  • Alfons Serrano,
  • Evelyn Acuña-Cruz,
  • Marta Cervera,
  • Marina Díaz-Beyá,
  • Belén Vidriales and
  • Pau Montesinos
  • + 22 authors

30 November 2024

Background/Objectives: Patients with relapsed/refractory (R/R) AML with FLT3 mutation (FLT3mut) have a dismal prognosis. FLT3mut offers a target for therapy in these patients. Gilteritinib (gilter) and quizartinib (quizar) have demonstrated efficacy...

  • Article
  • Open Access
19 Citations
6,149 Views
11 Pages

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)

  • Joshua D. Rosenblat,
  • Froukje E. deVries,
  • Zoe Doyle,
  • Roger S. McIntyre,
  • Gary Rodin,
  • Camilla Zimmermann,
  • Ernie Mak,
  • Breffni Hannon,
  • Christian Schulz-Quach and
  • Madeline Li
  • + 2 authors

7 January 2023

Antidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer and palliative care populat...

  • Article
  • Open Access
7 Citations
3,003 Views
11 Pages

Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study

  • Alexander Meleshko,
  • Nadzeya Piatrouskaya,
  • Katsiaryna Vashkevich,
  • Dzmitry Lutskovich,
  • Chuan Wang,
  • Dmitri Dormeshkin,
  • Natalia Savelyeva and
  • Mikalai Katsin

6 July 2022

We report, in brief, the results of a phase I, non-randomized study of idiotypic DNA vaccination in patients with B-cell non-Hodgkin’s lymphoma (ISRCTN31090206). The DNA sequence of lymphoma-derived immunoglobulin variable regions was used as a...

  • Review
  • Open Access
23 Citations
6,841 Views
24 Pages

A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis

  • Rachael Kee,
  • Michelle Naughton,
  • Gavin V. McDonnell,
  • Owain W. Howell and
  • Denise C. Fitzgerald

Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central nervous system (CNS). The most common form of MS is a relapsing–remitting disease characterised by acute episodes of demyelination associated with the b...

  • Article
  • Open Access
29 Citations
5,880 Views
15 Pages

The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model

  • Gabriele Di Sante,
  • Susanna Amadio,
  • Beatrice Sampaolese,
  • Maria Elisabetta Clementi,
  • Mariagrazia Valentini,
  • Cinzia Volonté,
  • Patrizia Casalbore,
  • Francesco Ria and
  • Fabrizio Michetti

18 March 2020

S100B is an astrocytic protein acting either as an intracellular regulator or an extracellular signaling molecule. A direct correlation between increased amount of S100B and demyelination and inflammatory processes has been demonstrated. The aim of t...

  • Case Report
  • Open Access
6,334 Views
11 Pages

The Effects of Intensive Rehabilitation Combined with Thiamine Treatment on Cognitive Recovery in a Case of Non-Alcoholic Wernicke–Korsakoff Syndrome

  • Cinzia Palmirotta,
  • Gilda Turi,
  • Serena Tagliente,
  • Michele Pansini,
  • Stefania De Trane and
  • Gianvito Lagravinese

14 February 2024

Wernicke–Korsakoff Syndrome (WKS) is a severe neurological disorder resulting from thiamine deficiency, commonly associated with alcohol consumption but also stemming from dietary imbalances or other clinical conditions. Cognitive deficits, aff...

  • Brief Report
  • Open Access
475 Views
10 Pages

Retrospective Analysis of Regorafenib Efficiency in Treatment of Metastatic Colorectal Cancer—Experience of Two Polish Comprehensive Cancer Centers

  • Magdalena Grabiec,
  • Dominika Raźniewska,
  • Tadeusz Kałużewski,
  • Magdalena Krakowska,
  • Barbara Radecka and
  • Piotr Potemski

1 January 2026

Objectives: Colorectal cancer is a major public health concern, ranking third in incidence among all malignant tumors both in Poland and globally. We conducted a retrospective study to evaluate the effectiveness of regorafenib in patients with metast...

  • Review
  • Open Access
12 Citations
4,501 Views
15 Pages

Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors

  • Ahmad Alharbi,
  • Attiah Khobrani,
  • Afnan Noor,
  • Waad Alghamdi,
  • Abdulmalik Alotaibi,
  • Mohammed Alnuhait and
  • Abdul Haseeb

Introduction: Immune checkpoint inhibitors (ICIs) are recommended for various types of cancer. On the other hand, these ICIs may cause immune-related adverse events (irAEs). Lichen sclerosus (LS) and lichen planus (LP) are two distinct phenotypes of...

  • Article
  • Open Access
57 Citations
7,606 Views
14 Pages

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG

  • Mareike Rasche,
  • Martin Zimmermann,
  • Emma Steidel,
  • Todd Alonzo,
  • Richard Aplenc,
  • Jean-Pierre Bourquin,
  • Heidrun Boztug,
  • Todd Cooper,
  • Alan S. Gamis and
  • Dirk Reinhardt
  • + 15 authors

12 May 2021

Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-...

  • Review
  • Open Access
19 Citations
4,330 Views
16 Pages

20 November 2021

Leukemia stem cells (LSCs, also known as leukemia-initiating cells) not only drive leukemia initiation and progression, but also contribute to drug resistance and/or disease relapse. Therefore, eradication of every last LSC is critical for a patient’...

  • Review
  • Open Access
11 Citations
5,825 Views
16 Pages

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option

  • Stefano Molica,
  • Constantine Tam,
  • David Allsup and
  • Aaron Polliack

23 July 2023

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is,...

  • Article
  • Open Access
18 Citations
3,469 Views
14 Pages

A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer

  • Francesco Izzo,
  • Vincenza Granata,
  • Roberta Fusco,
  • Valeria D’Alessio,
  • Antonella Petrillo,
  • Secondo Lastoria,
  • Mauro Piccirillo,
  • Vittorio Albino,
  • Andrea Belli and
  • Raffaele Palaia
  • + 5 authors

5 September 2021

Background: Eighty percent of patients with pancreatic adenocarcinoma present a locally advanced or metastatic disease at diagnosis and are not eligible for surgery if not with palliative intent. In cases of locally advanced disease (LAPC), the combi...

  • Case Report
  • Open Access
6 Citations
4,620 Views
8 Pages

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients

  • Christof Vulsteke,
  • Laurens De Cocker,
  • Alfonso Gómez de Liaño,
  • Cristina Montesdeoca,
  • Astrid De Meulenaere,
  • Lieselot Croes,
  • Danielle Delombaerde,
  • Bernadett Szabados and
  • Thomas Powles

Enfortumab vedotin (EV), an antibody–drug conjugate directed against Nectin-4, significantly prolonged survival compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who previously received plati...

  • Article
  • Open Access
25 Citations
3,749 Views
15 Pages

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study

  • Barbara Bailly-Caillé,
  • Diane Kottler,
  • Rémy Morello,
  • Marie Lecornu,
  • William Kao,
  • Emmanuel Meyer,
  • Anne Dompmartin and
  • Jean-Matthieu L’Orphelin

13 January 2023

Background: Cemiplimab is a monoclonal antibody targeting the PD-1, and phase II trials have shown its efficacy in the treatment of advanced cutaneous squamous cell carcinoma in patients who are not candidates for curative surgery or radiation therap...